New system speeds screening of drug-delivering nanoparticles

James Dahlman and Phil Santangelo are serving to to outline an evolving period in medication, one by which messenger ribonucleic acid—mRNA—might be delivered on to cells to battle in opposition to illness. And their newest groundbreaking research may clear the best way to quicker therapeutic discoveries.

Lengthy earlier than the COVID-19 pandemic put a world highlight on mRNA-based vaccines, these two researchers within the Wallace H. Coulter Division of Biomedical Engineering at Georgia Tech and Emory College had been combining their distinct skillsets to leverage the medical potential of mRNA.

“Our work could be very suitable,” stated Dahlman, affiliate professor and McCamish Basis Early Profession Professor. “Phil’s lab designs and manufactures actually high-quality mRNA, and my lab develops the lipid nanoparticles to ship it.”

Therapeutics made out of mRNA or DNA maintain promise in addressing plenty of illnesses, defined Santangelo, a professor in Coulter BME, “however they are not a lot good if they can not get the place they should go. If you happen to make cargo, which is basically what we do in my lab, you want supply, so James and I’ve a really pure collaboration.”

Their partnership, which started when Dahlman arrived at Georgia Tech in 2016, constantly yields outcomes printed in high-impact journals and garners beneficiant analysis grants from federal businesses, together with the Nationwide Institutes of Well being (NIH) and the Protection Superior Analysis Initiatives Company (DARPA).

That features a latest flood of cutting-edge papers: two in Nature Biomedical Engineering (from October 2021, and a forthcoming research) in addition to their newest publication, launched Feb. 7 in Nature Nanotechnology.

“We’re reporting an improved barcoding system that might make animal pre-clinical nanoparticle research extra predictive, rushing up the event of RNA therapies,” Dahlman stated.

A number of years in the past, Dahlman and collaborators developed a method known as “DNA barcoding,” which permits for the speedy, simultaneous screening of a lot of his custom-made supply automobiles—what are known as lipid nanoparticles, or LNPs. Scientists insert distinctive snippets of DNA into totally different LNPs, that are injected into mice. Genetic sequencing is then used to find out which barcodes have reached which particular targets.

The brand new system described in Nature Nanotechnology takes the screening course of a step additional.

“Lipid nanoparticles are normally developed in mice, however whenever you transfer them into one other species, like a non-human primate—as a result of that is the pure development, a primate is extra like a human—they incessantly do not work as nicely,” Santangelo stated. “Once they do not, you need to return and make changes.”

However what when you may streamline the method?

The genes that have an effect on LNP supply differ between pre-clinical species and people, although the extent of these variations is unknown as a result of research evaluating nanoparticle supply throughout species have been very tough to carry out. Till now. To hurry that course of, the researchers developed a brand new testing system they’re calling Species Agnostic Nanoparticle Supply Screening, or SANDS.

Utilizing SANDS, the group in contrast nanoparticle supply concurrently in mouse, primate, and residing human cells, all inside specifically engineered mice.

“We will truly put the identical group of nanoparticles in all three and evaluate supply throughout species,” Dahlman stated. “We discovered what you would possibly count on: supply within the primate cells predicted very well how supply within the human cells would go, whereas the mouse cells had been much less predictive.”

In contrast to the earlier barcoding system, which labored nicely in mouse cells, SANDS wanted a distinct form of marker for screening, a molecule known as reporter mRNA. Santangelo’s lab developed one, “and it mainly will get across the limitations of the previous system,” he stated. “Now we will display new lipid nanoparticles in mice with primate and human cells.”

SANDS already is facilitating additional research for the analysis group.

Going ahead, Dahlman and Santangelo imagine that deeper understanding of the totally different mechanisms driving supply in mouse cells and different cells will end in a extra environment friendly choice course of for LNPs, making pre-clinical nanoparticle research extra predictive and accelerating the event of RNA therapies.

That sense of constructing momentum has been form of a theme for the Dahlman-Santangelo partnership because it started. Dahlman remembered interviewing at Georgia Tech and Emory and being instantly impressed when he met Santangelo.

“I defined to him my imaginative and prescient for barcoding, and he instantly received it; he defined to me his imaginative and prescient for bettering payloads, and I instantly received that,” Dahlman stated. “You possibly can have the world’s finest nanoparticle, however when you do not put optimized mRNA in it, that is not going to be any good.”

They instantly acknowledged the worth and the need for collaboration, particularly as a result of, as Santangelo put it, “This can be a wildly aggressive time in mRNA analysis.”

The tempo of their work displays that, too. Their October research in Nature Biomedical Engineering reported improvement of an LNP designed particularly to be delivered by a nebulizer into the lungs. Of their experiments, it efficiently delivered therapeutic mRNA and guarded mice from a deadly flu. They have a number of extra papers nearing publication.

And there is work quickly to be funded by the Wellcome Leap program that features a undertaking targeted on mRNA-encoded antibodies for the lung. They’re additionally creating what could possibly be one other game-changer in vaccinations—what Santangelo described as “a brand new kind of method that has lots of potential: The essential concept is to have the flexibility to vaccinate in opposition to many pathogens without delay.”

Finally, although, it comes again to having the very best automobile to ship the potent payload; you’ll be able to’t actually have one with out the opposite. The Dahlman-Santangelo analysis partnership is complementary in different methods as nicely, with Dahlman’s lab doing lots of the sequencing and Santangelo’s lab doing lots of the imaging.

“It implies that we will write papers which can be rather more full,” Santangelo stated. “It consists of the entire knowledge, and it might probably have sequencing, it might probably have imaging, it has fancy cargoes, it has cool supply. You set collectively all of these items, and you’ve got a pleasant bundle.”